RAGE Biotech
Kevin Pfleger serves as the Director of Biomedical and Health Innovation at The University of Western Australia, a position held since October 2002, alongside multiple roles including Professor and Director of the WA Life Sciences Innovation Hub. Experienced in various leadership and advisory capacities, Pfleger is a member of several panels and committees, including the WA Health and Medical Research Strategy and the Health and Medical Life Sciences Industry Advisory Group. Additional roles encompass Chair positions at Biodesign Australia and Perth Biodesign, and leadership at the Harry Perkins Institute of Medical Research. Pfleger's academic background includes degrees from the University of Cambridge and The University of Edinburgh, specializing in pharmacology and molecular endocrinology.
This person is not in any teams
RAGE Biotech
RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor. Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem. RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.